
5-Year Phase 2 Data Show 0% Recurrence Rate After Surgery Omission in Select Patients With Invasive Breast Cancer
The omission of surgery following neoadjuvant systemic therapy proved feasible in patients with invasive HER2-positive breast cancer and invasive triple-negative breast cancer (TNBC), according to findings from a nonrandomized phase 2 trial (NCT02945579), …